DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
Tekla HarjuAnri Hurme-NiiranenMaria Suo-PalosaariStine Nygaard NielsenReetta HinttalaKjeld SchmiegelowJohanna UusimaaArja HarilaRiitta NiinimäkiPublished in: The pharmacogenomics journal (2023)
Hepatotoxicity is a frequent complication during maintenance therapy of acute lymphoblastic leukemia (ALL) with 6-mercaptopurine and methotrexate. Elevated levels of methylated 6-mercaptopurine metabolites (MeMP) are associated with hepatotoxicity. However, not all mechanisms are known that lead to liver failure in patients with ALL. Variants in the POLG gene, which encodes the catalytic subunit of mitochondrial DNA polymerase gamma (POLG1), have been related to drug-induced hepatotoxicity, for example, by sodium valproate. The association of common POLG variants with hepatotoxicity during maintenance therapy was studied in 34 patients with childhood ALL. Of the screened POLG variants, four different variants were detected in 12 patients. One patient developed severe hepatotoxicity without elevated MeMP levels and harbored a heterozygous POLG p.G517V variant, which was not found in the other patients.
Keyphrases
- drug induced
- copy number
- liver injury
- mitochondrial dna
- acute lymphoblastic leukemia
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- ejection fraction
- liver failure
- newly diagnosed
- prognostic factors
- dna methylation
- hepatitis b virus
- genome wide
- gene expression
- mesenchymal stem cells
- cell free
- stem cells
- case report
- cell therapy
- protein kinase
- smoking cessation